The microbiome and human cancer
Open accessThe DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index; 65 of the 179 sources its claims cite were checked for support.
Abstract
BACKGROUND: Historical accounts linking cancer and microbes date as early as four millennia ago. After establishment of the germ theory of infectious diseases, clinical research of microbial influences on cancer began in 1868, when William Busch reported spontaneous tumor regressions in patients with Streptococcus pyogenes infections. Over the next century, poor reproducibility, erroneous microbiological claims, and severe toxicity led many to discount the role of bacteria in carcinogenesis and cancer therapy. However, these studies provided the first crude demonstrations of cancer immunotherapy. Contemporaneously, the viral theory of cancer flourished, spurred by the 1911 discovery of Rous sarcoma virus, which transformed benign tissue into malignant tumors in chickens. The decades-long search to find viruses behind every human cancer ultimately failed, and many cancers have been linked to somatic mutations. Now the field is encountering intriguing claims of the importance of microbes, including bacteria and fungi, in cancer and cancer therapy. This Review critically evaluates this evidence in light of modern cancer biology and immunology, delineating roles for microbes in cancer by examining advances in proposed mechanisms, diagnostics, and modulation strategies. ADVANCES: Few microbes directly cause cancer, but many seem complicit in its growth, often acting through the host’s immune system; conversely, several have immunostimulatory properties. Mechanistic analyses of gut microbiota–immune system interactions reveal powerful effects on antitumor immunity by modulating primary and secondary lymphoid tissue activities. Many of these pathways invoke Toll-like receptor–initiated cytokine signaling, but microbial metabolic effects and antigenic mimicry with cancer cells are also important. In preclinical models, microbial metabolites also regulate phenotypes of tumor somatic mutations and modulate immune checkpoint inhibitor efficacy. Emerging evidence suggests that intratumoral bacteria exist and are active, with overlapping immunohistochemistry, immunofluorescence, electron microscopy, and sequencing data in ~10 cancer types. Preliminary studies further suggest that fungi and bacteriophages contribute to gastrointestinal cancers. However, the abundance of intratumoral microbial cells is low relative to cancer cells, and knowledge of their functional repertoire and potency remains limited. Further validation of their prevalence and impact is needed in diverse cohorts and therapeutic contexts. The immunomodulatory effects of host microbiota have reinvigorated efforts to change their composition as a form of immunotherapy. Despite extensive preclinical evidence, translation of microbiota modulation approaches into humans has not yet materialized into commercialized therapies. Synthetic biology approaches are also gaining traction, with engineered bacterial cancer therapies in preclinical and clinical trial settings. OUTLOOK: A better understanding of the roles of microbes in cancer provides an opportunity to improve each stage of the cancer care cycle, but major challenges remain. Concerted efforts to characterize cancer-associated microbiota among tumor, stool, and blood samples with gold-standard contamination controls would tremendously aid this progress. This would be analogous to The Cancer Genome Atlas’s role in characterizing the cancer somatic mutation landscape. Large-scale clinical trials are currently testing the efficacy of microbiota modulation approaches, ranging from dietary modifications to intratumorally injected, engineered bacteria. These bacterial cancer therapies, if safe and effective, could tremendously expand the cancer therapy armamentarium. Altogether, integrating the host-centric and microbial viewpoints of cancer may improve patient outcomes while providing a nuanced understanding of cancer-host-microbial evolution. Opportunities for microbes to affect cancer care.: Diagnosis: Cancer-specific, blood-borne microbial DNA may complement cell-free tumor DNA (ctDNA). Prognosis: Gut and intratumoral microbiota may stratify patient outcomes (NR, nonresponder; R, responder; TME, tumor microenvironment). Therapy: Intratumor injection of CD47 nanobody (CD47nb)–producing Escherichia coli may create systemic antitumor immunity by enhancing dendritic cell (DC) phagocytosis, lymph node (LN) antigen (Ag) presentation, and cytotoxic T lymphocyte (CTL) activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
28 Valid · 4 Not valid · 64 Not checked · 22 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
§ The microbiome and human cancer > Abstract > OUTLOOK:
What the sources say
- Supportedcites [27] Sender R, Fuchs S, Milo R, Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 14, e1002533 (2016). 27541692 PMC4991899 source
The Results section 'The Ratio of Bacteria to Human Cells in the Adult Body' states B/H = 1.3 (3.8·10^13 bacteria vs 3.0·10^13 human cells in the 70 kg reference man), explicitly described as 'about 1:1' replacing the 10:1 or 100:1 values. The Abstract likewise says the number of bacteria is 'of the same order as the number of human cells', and Table 3 shows the ratio stays near parity (1.3–2.3) across women, infants, elderly and obese segments. The paper also operationally equates 'microbial cells' with bacteria, since bacteria dominate the microbiome by 2–3 orders of magnitude. (LLM, conf=0.92)
- Disputedcites [28] Belkaid Y, Naik S, Compartmentalized and systemic control of tissue immunity by commensals. Nat. Immunol 14, 646– 653 (2013). 23778791 PMC3845005 sourceExperimental — accuracy not yet measured
Our copy states the opposite ratio: in 'Distinct anatomical sites have unique commensal communities' it says that with an estimated 100 trillion cells, commensals outnumber host cells by at least a factor of ten (and encode at least 100-fold more unique genes). No passage anywhere in the paper describes microbial and human cell numbers as roughly equal; searches for 'outnumber host cells / 100 trillion' and for 'number of microbial cells relative to human cells equal' returned only that sentence and unrelated topical passages. The parenthetical the citing sentence attributes to this source therefore contradicts what the source asserts. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [29] Fung TC, Olson CA, Hsiao EY, Interactions between the microbiota, immune and nervous systems in health and disease. Nat. Neurosci 20, 145– 155 (2017). 28092661 PMC6960010 sourceExperimental — accuracy not yet measured
The Abstract of Fung, Olson & Hsiao (2017) states that 'The human gastrointestinal tract is colonized by trillions of microorganisms collectively termed the gut microbiota', which supports the framing that the human body harbours an enormous microbial population, but locates it in the GI tract rather than the whole body. No passage in our copy compares microbial numbers to the number of human cells or states anything like a ~1:1 (or 10:1) ratio; searches for 'microbial cells outnumber human cells ratio tenfold', 'number of human cells', and microbiota diversity/abundance returned only the trillions-of-microorganisms statement and unrelated neuroimmune content. The quantitative equivalence attributed to this source is therefore not in our copy. (LLM, conf=0.72)
- Partly supportedcites [30] Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF, The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 359, 1366– 1370 (2018). 29567708 sourceExperimental — accuracy not yet measured
The only quantitative statement in our copy is in 'Early steps: A role for the microbiome in cancer': 'The human gut microbiome contains ~3 × 10^13 bacteria, most of which are commensals (5)' — a gut-restricted bacterial count, credited to reference 5. Nothing in our copy states a number of human cells or compares microbial counts to human cell counts, so the claim's central equivalence ('roughly equal to the number of human cells') and the whole-body scope are not supported by this source. Searches for 'number of human cells', 'microbial cells outnumber human cells', and '10^14' returned no such comparison; the paper does describe the host as a 'meta-organism' shaped by the gut microbiome, without any ratio to host cells. (LLM, conf=0.65)
- Not checked yetcites [31] Garrett WS, Cancer and the microbiota. Science. 348, 80– 86 (2015). 25838377 PMC5535753 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Increasing evidence suggests an important additional category of “complicit” microbes and microbial functions that promote carcinogenesis but are insufficient to cause cancer (18, 20, 25, 38, 44–47).”
§ The microbiome and human cancer > Overview of the cancer microbiome
What the sources say
- Supportedcites [18] Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, Ameh S, Sandel D, Liang XS, Mazzilli S, Whary MT, Meyerson M, Germain R, Blainey PC, Fox JG, Jacks T, Commensal Microbiota Promote Lung Cancer Development via γδ T Cells. Cell. 176, 998– 1013.e16 (2019). 30712876 PMC6691977 source
The Results (page unavailable) show that commensal microbiota increased tumor growth in mice whose lung tumors were initiated by Kras activation and p53 deletion. The Discussion (page unavailable) likewise describes early tumor development arising from those genetic changes, with local microbiota amplifying the response that promotes progression. This supports the cited paper as an example of microbes that promote carcinogenesis without being sufficient to initiate it. (LLM, conf=0.88)
- Partly supportedcites [20] Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, Shadaloey SA, Wu D, Preiss P, Verma N, Guo Y, Saxena A, Vardhan M, Diskin B, Wang W, Leinwand J, Kurz E, Kochen Rossi JA, Hundeyin M, Zambrinis C, Li X, Saxena D, Miller G, The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 574, 264– 267 (2019). 31578522 PMC6858566 sourceExperimental — accuracy not yet measured
The paper reports that fungal ablation protected against pancreatic tumor progression and that repopulation with Malassezia accelerated it (Abstract; page unavailable). Its experiments used mice with oncogenic Kras or implanted tumor cells, and it does not establish that the fungi are insufficient to cause cancer on their own. It also says whether fungal changes are a cause or consequence of oncogenesis is difficult to answer fully. (LLM, conf=0.86)
- Partly supportedcites [25] Tsay J-CJ, Wu BG, Sulaiman I, Gershner K, Schluger R, Li Y, Yie T-A, Meyn P, Olsen E, Perez L, Franca B, Carpenito J, Iizumi T, El-Ashmawy M, Badri M, Morton JT, Shen N, He L, Michaud G, Rafeq S, Bessich JL, Smith RL, Sauthoff H, Felner K, Pillai R, Zavitsanou A-M, Koralov SB, Mezzano V, Loomis CA, Moreira AL, Moore W, Tsirigos A, Heguy A, Rom WN, Sterman DH, Pass HI, Clemente JC, Li H, Bonneau R, Wong K-K, Papagiannakopoulos T, Segal LN, Lower airway dysbiosis affects lung cancer progression. Cancer Discov. (2020), doi: 10.1158/2159-8290.CD-20-0263. PMC7858243 33177060 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable in our copy) says that oral commensals such as Veillonella contribute to a pro-tumor immune environment and progression of existing non-small-cell lung cancer. The Methods describe introducing Veillonella after lung cancer was established in mice. This supports a role in progression, but the paper does not establish that these microbes or their functions are insufficient to cause cancer on their own. (LLM, conf=0.82)
- Supportedcites [38] Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL, Anders RA, Giardiello FM, Wick EC, Wang H, Wu S, Pardoll DM, Housseau F, Sears CL, Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 359, 592– 597 (2018). 29420293 PMC5881113 source
The paper reports that, in carcinogen-treated mice, either bacterial strain alone produced few to no tumors, whereas co-colonization produced pronounced tumor induction. It proposes complementary microbial mechanisms that enhance carcinogenesis, supporting the citing sentence’s point that microbes can contribute to cancer without being sufficient on their own. The supplied copy gives no page numbers. (LLM, conf=0.85)
- Supportedcites [44] Kadosh E, Snir-Alkalay I, Venkatachalam A, May S, Lasry A, Elyada E, Zinger A, Shaham M, Vaalani G, Mernberger M, Stiewe T, Pikarsky E, Oren M, Ben-Neriah Y, The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature. 586, 133– 138 (2020). 32728212 PMC7116712 source
The Discussion (page unavailable) reports that the native gut microbiota or gallic acid converts mutant p53’s tumour-suppressive effect into oncogenic activity. In “Gallic acid mimics the microbiota effect” (page unavailable), gallic acid promotes dysplasia in mice with CKIα ablation and mutant p53, but has no effect on tumorigenesis in the tested mice with wild-type p53. This supports the cited paper as an example of a microbial function that promotes carcinogenesis in a susceptible context rather than causing it on its own. (LLM, conf=0.87)
- Partly supportedcites [45] Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF, Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 360 (2018), doi: 10.1126/science.aan5931. PMC6407885 29798856 sourceExperimental — accuracy not yet measured
The Results and ‘Alterations in the gut microbiome suppress liver tumors in multiple mouse models’ sections report that changing gut bacteria or bile-acid metabolism changes liver tumor growth, supporting a role for microbial functions in promoting cancer. The experiments used MYC-induced tumors or implanted tumor cells; they do not establish the broader claim that these microbes or functions are insufficient to cause cancer on their own. No page numbers are provided in our copy. (LLM, conf=0.84)
- Partly supportedcites [46] Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A, Tagliabue E, Sfondrini L, Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. Cell Rep. 24, 3528– 3538 (2018). 30257213 sourceExperimental — accuracy not yet measured
The Discussion says lung commensal microbes can provide immunosuppressive signals, and the results show that changing the lung microbiota reduced metastasis implantation in mice given tumor cells. This supports a microbial role in facilitating cancer spread, but the paper does not establish a general category of “complicit” microbes that promote carcinogenesis, or explicitly assess whether those microbes can cause cancer on their own. The indexed passages provide section labels but no page numbers. (LLM, conf=0.83)
- Partly supportedcites [47] Meisel M, Hinterleitner R, Pacis A, Chen L, Earley ZM, Mayassi T, Pierre JF, Ernest JD, Galipeau HJ, Thuille N, Bouziat R, Buscarlet M, Ringus DL, Wang Y, Li Y, Dinh V, Kim SM, McDonald BD, Zurenski MA, Musch MW, Furtado GC, Lira SA, Baier G, Chang EB, Eren AM, Weber CR, Busque L, Godley LA, Verdú EF, Barreiro LB, Jabri B, Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 557, 580– 584 (2018). 29769727 PMC6238954 sourceExperimental — accuracy not yet measured
The Abstract reports that microbial signals drive pre-leukaemic myeloproliferation in Tet2-deficient mice, supporting a role for microbes in a precancerous condition that also requires host susceptibility. But the Abstract and Extended Data explicitly say whether those signals promote the additional mutations leading to leukaemia remains undetermined; the paper does not establish that they promote cancer itself. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Experimental evidence also implicates several microbes with virulence factors that amplify tumorigenesis via E-cadherin/Wnt/β-Catenin signaling, including FadA from Fusobacterium nucleatum and AvrA from several Salmonella strains (42, 43).”
§ The microbiome and human cancer > Overview of the cancer microbiome
What the sources say
- Partly supportedcites [42] Silva-García O, Valdez-Alarcón JJ, Baizabal-Aguirre VM, Wnt/β-Catenin Signaling as a Molecular Target by Pathogenic Bacteria. Front. Immunol 10, 2135 (2019). 31611869 PMC6776594 sourceExperimental — accuracy not yet measured
Our copy supports the AvrA/Salmonella half: the 'Salmonella enterica sv Typhimurium' section states that AvrA enhances β-catenin deubiquitination/stability and induces Wnt2, Wnt3, Wnt6, Wnt9a and Wnt11 (also tabulated in Table 1, Introduction), and concludes these effects 'may contribute to chronic disease and cell proliferation, leading to tumor development and cancer.' However, Fusobacterium nucleatum and FadA appear nowhere in our copy (searched: Fusobacterium, FadA, nucleatum); Table 1's inventory of bacteria with Wnt/β-catenin-affecting virulence factors does not include them, so that half of the claim is not attributable to this source. Additionally, the E-cadherin arm of the mechanism is described here for B. fragilis toxin, H. parasuis and H. pylori CagA, not for AvrA, and the tumorigenic outcome for AvrA is stated as a possibility ('may promote,' 'tempting to speculate') rather than the asserted amplification of tumorigenesis the citing sentence carries. (LLM, conf=0.82)
- Supportedcites [43] Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW, Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 14, 195– 206 (2013). 23954158 PMC3770529 source
Our copy of Rubinstein et al. (2013) states exactly the FadA/F. nucleatum half of the sentence: the INTRODUCTION summary reports that 'FadA modulates E-cadherin and activates β-catenin signaling, leading to increased expression of transcription factors, oncogenes, Wnt genes... as well as growth stimulation of CRC cells', the RESULTS (FadAc activates E-cadherin-mediated cellular signaling) show β-catenin nuclear translocation and CRT/TOPFlash activation dependent on E-cadherin and β-catenin, and the xenograft RESULTS (p. Fig. 6) show FadA increased HCT116 tumor growth by 20% via E-cadherin binding — i.e., a microbial virulence factor amplifying tumorigenesis through E-cadherin/Wnt/β-catenin. The DISCUSSION also frames the paper as reporting 'a mechanism by which Fn modulates E-cadherin/β-catenin signaling'. The AvrA/Salmonella clause of the citing sentence is carried by the companion citation in the (42, 43) pair; our copy contains no mention of Salmonella or AvrA (searched: AvrA, Salmonella, other bacterial virulence factors), so it neither supports nor contradicts that half — the only other microbe it credits with an E-cadherin/β-catenin mechanism is Bacteroides fragilis enterotoxin BFT (Wu et al., 1998; 2003). (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The TME comprises not only stromal, tumor, endothelial cells, and hematopoietic progenitor-derived immune components, but also a dense network of adrenergic nerve fibres that influence oncogenesis in brain and non-brain cancers (94–97).”
§ The microbiome and human cancer > Overview of the cancer microbiome > Mechanisms and interactions between the gut and tumor microbiome
What the sources say
- Partly supportedcites [94] Amit M, Takahashi H, Dragomir MP, Lindemann A, Gleber-Netto FO, Pickering CR, Anfossi S, Osman AA, Cai Y, Wang R, Knutsen E, Shimizu M, Ivan C, Rao X, Wang J, Silverman DA, Tam S, Zhao M, Caulin C, Zinger A, Tasciotti E, Dougherty PM, El-Naggar A, Calin GA, Myers JN, Loss of p53 drives neuron reprogramming in head and neck cancer. Nature. 578, 449– 454 (2020). 32051587 PMC9723538 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes adrenergic neo-nerves in the oral-cancer microenvironment and says neo-neural networks provide signals that coordinate cancer progression. The cited paper does not establish a dense adrenergic network in both brain and non-brain cancers, or document the sentence’s full list of microenvironmental cell types. (LLM, conf=0.87)
- Not checked yetcites [95] Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, Körber C, Kardorff M, Ratliff M, Xie R, Horstmann H, Messer M, Paik SP, Knabbe J, Sahm F, Kurz FT, Acikgöz AA, Herrmannsdörfer F, Agarwal A, Bergles DE, Chalmers A, Miletic H, Turcan S, Mawrin C, Hänggi D, Liu H-K, Wick W, Winkler F, Kuner T, Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 573, 532– 538 (2019). 31534219 source
- Partly supportedcites [96] Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, McCabe BD, Galván JA, Robinson HPC, Zlobec I, Ciriello G, Hanahan D, Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 573, 526– 531 (2019). 31534217 PMC6837873 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) supports a narrower point: interactions with neurons promote growth of breast-cancer metastases in the brain. The Introduction (page unavailable) also reports earlier findings on NMDAR signalling in pancreatic cancers. Neither passage describes a dense network of adrenergic nerve fibres or establishes the stated list of tumour-microenvironment components; the Discussion treats comparable interactions with peripheral nerves as a question for future study. (LLM, conf=0.84)
- Partly supportedcites [97] Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, Tam LT, Espenel C, Ponnuswami A, Ni L, Woo PJ, Taylor KR, Agarwal A, Regev A, Brang D, Vogel H, Hervey-Jumper S, Bergles DE, Suvà ML, Malenka RC, Monje M, Electrical and synaptic integration of glioma into neural circuits. Nature. 573, 539– 545 (2019). 31534222 PMC7038898 sourceExperimental — accuracy not yet measured
The Discussion (page not provided) identifies neurons as part of the glioma microenvironment and describes neuronal signaling that drives glioma growth. The paper does not establish a dense network of adrenergic fibres, the listed stromal and immune-cell composition, or effects on non-brain cancers. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“intratumor microbes have been reported to have cancer-specific effects on (i) gastrointestinal and urinary tract mutagenesis via secreted genotoxins, most notably pks+ E. coli-derived colibactin and B. fragilis-derived toxin (22, 37, 38, 40, 41)”
§ The microbiome and human cancer > Overview of the cancer microbiome > Mechanisms and interactions between the gut and tumor microbiome
What the sources say
- Not checked yetcites [22] Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM, Nomburg J, Gurjao C, Manders F, Dalmasso G, Stege PB, Paganelli FL, Geurts MH, Beumer J, Mizutani T, Miao Y, van der Linden R, van der Elst S, Genomics England Research Consortium, Garcia KC, Top J, Willems RJL, Giannakis M, Bonnet R, Quirke P, Meyerson M, Cuppen E, van Boxtel R, Clevers H, Mutational signature in colorectal cancer caused by genotoxic pks E. coli. Nature. 580, 269– 273 (2020). 32106218 PMC8142898 source
- Partly supportedcites [37] Wilson MR, Jiang Y, Villalta PW, Stornetta A, Boudreau PD, Carrá A, Brennan CA, Chun E, Ngo L, Samson LD, Engelward BP, Garrett WS, Balbo S, Balskus EP, The human gut bacterial genotoxin colibactin alkylates DNA. Science. 363 (2019), doi: 10.1126/science.aar7785. PMC6407708 30765538 sourceExperimental — accuracy not yet measured
The DNA-adduct experiments report colibactin-associated DNA damage in colonic epithelial cells and in mice colonized with pks+ E. coli. The Conclusions say resulting mutations may contribute to cancer, but do not establish cancer-specific mutagenesis. This paper does not support the sentence’s urinary-tract or B. fragilis-toxin components. (LLM, conf=0.87)
- Partly supportedcites [38] Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL, Anders RA, Giardiello FM, Wick EC, Wang H, Wu S, Pardoll DM, Housseau F, Sears CL, Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 359, 592– 597 (2018). 29420293 PMC5881113 sourceExperimental — accuracy not yet measured
The passage labeled Abstract (page not provided) identifies colibactin and B. fragilis toxin as secreted oncotoxins and reports increased colonic epithelial DNA damage and tumorigenesis when mice were cocolonized with the two bacteria. The paper concerns colonic mucosal biofilms in patients with familial adenomatous polyposis and colon-tumor models; it does not establish urinary-tract mutagenesis or effects of intratumor microbes across cancers. It attributes the observed DNA damage specifically to colibactin, rather than showing that B. fragilis toxin itself causes mutagenesis. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
59 more claims · 12 with their cited sources checked
Create a free account to see all 118 claims and to verify the 114 references still open.
- It may state two separate claims as one. 52
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The gut microbiome is increasingly recognized as a modifiable risk factor in multiple cancer types, including colorectal, gastric, and pancreatic cancers [12,41–43]”
From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recognition of the pivotal role of the microbiome in cancer initiation, progression, and treatment response has opened new avenues for therapeutic intervention [7–12]”
From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [12]
In the citing paper
“Parallel studies have demonstrated that the composition of the intestinal microbiota exhibits numerous disease-relevant changes in cancer patients.”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The microbiome and human cancer > Overview of the cancer microbiome
“just 11 are labeled human carcinogens, or “oncomicrobes,” by the International Association for Cancer Registries (IACR) (36).”
§ The microbiome and human cancer > References
“36. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Biological agents. Volume 100 B. A review of human carcinogens.”
Citations
Cites
1 retracted
RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciolek, T., Janssen, S., Metcalf, J., Song, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2095-1 · Cited by 989
Self-citationRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Self-citationThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationRevised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425 · cited 1×
“1 to 1% are archaea and eukarya (including fungi) (27, 48).”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Moreover, observations in humans and mice of gut microbes that stratify therapy response, particularly immunotherapy (16, 17, 21, 26), have not uncommonly shown varying taxonomic differences that persist despite uniform bioinformatic reanalyses, although there is greater concordance when examining functional profiles…”
BackgroundSelf-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 1×
“Molecular mimicry between cancer and microbial antigens has also been hinted (82) and recently studied in depth (83).”
BackgroundCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“thatmediates Toll-like receptor 4 (TLR4)– and IL-12–dependent TH1 responses and therapeutic efficacy (70); (iii) inhibition of programmed cell death protein 1 and/or its ligand [PD-(L)1] leads to T cell priming against melanoma and is more effective when hosts harbor Bifidobacteria species in their microbiome (21, 71)…”
Background
Research works printed but not linked: 2
- W. Busch, Aus der Sitzung der medicinischen Section vom 13 November 1867. Berl Klin Wochenschr 5, 137 (1868).
- T. J. Glover, The bacteriology of cancer. Canada Lancet Pract. 75, 92–111 (1930).
Cited by
Items 201–300 of 1,001
Gut dysbiosis and age-related neurological diseases in females
Korf, J. M., Ganesh, B. P., & McCullough, L. D. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105695 · Cited by 49
The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
Pan-cancer atlas of tumor-resident microbiome, immunity and prognosis
Sheng, D., Jin, C., Yue, K., Yue, M., Liang, Y., Xue, X., Li, P., Zhao, G., & Zhang, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217077 · Cited by 48
Ding, T., Liu, C., & Li, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02227-8 · Cited by 48
Acetylation in pathogenesis: Revealing emerging mechanisms and therapeutic prospects
Jiang, N., Li, W., Jiang, S., Xie, M., & Liu, R. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115519 · Cited by 47
Role of the gut microbiota in tumorigenesis and treatment
Liu, Q., Yang, Y., Pan, M., Yang, F., Yu, Y., & Qian, Z. (2024) · Theranostics · doi:10.7150/thno.91700 · Cited by 47
Lou, F., Yan, L., Luo, S., Dong, Y., Xu, J., Kang, N., Wang, H., Liu, Y., Pu, J., Yang, B., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-333479 · Cited by 47
New opportunities for immunomodulation of the tumour microenvironment using chemical tools
Su, J., Li, W., & Li, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00486k · Cited by 47
Intratumoral microbiota: implications for cancer onset, progression, and therapy
Wu, J., Zhang, P., Mei, W., & Zeng, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1301506 · Cited by 46
Engineered Microorganisms for Advancing Tumor Therapy
Jia, J., Wang, X., Lin, X., & Zhao, Y. (2024) · Advanced Materials · doi:10.1002/adma.202313389 · Cited by 46
Cancer metabolism and dietary interventions
Qian, L., Zhang, F., Yin, M., & Lei, Q. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0461 · Cited by 47
Zhao, S.-S., Chen, L., Yang, J., Wu, Z.-H., Wang, X., Zhang, Q., Liu, W., & Liu, H. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02612-22 · Cited by 46
Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
Noelle, R. J., Lines, J. L., Lewis, L. D., Martell, R. E., Guillaudeux, T., Lee, S. W., Mahoney, K. M., Vesely, M. D., Boyd-Kirkup, J. D., Nambiar, D. K., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1225081 · Cited by 45
The emerging role of bacterial extracellular vesicles in human cancers
Liang, A., Korani, L., Yeung, C. L. S., Tey, S. K., & Yam, J. W. P. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12521 · Cited by 45
Is Candida albicans a contributor to cancer? A critical review based on the current evidence
Wang, X., Zhang, W., Wu, W., Wu, S., Young, A., & Yan, Z. (2023) · Microbiological Research · doi:10.1016/j.micres.2023.127370 · Cited by 44
Intratumour microbiome of pancreatic cancer
Guan, S.-W., Lin, Q., & Yu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.713 · Cited by 45
Serum Essential Elements and Survival after Cancer Diagnosis
Lubiński, J., Lener, M. R., Marciniak, W., Pietrzak, S., Derkacz, R., Cybulski, C., Gronwald, J., Dębniak, T., Jakubowska, A., Huzarski, T., et al. (2023) · Nutrients · doi:10.3390/nu15112611 · Cited by 44
Unveiling the intratumoral microbiota within cancer landscapes
Che, S., Yan, Z., Feng, Y., & Hai, Z. (2024) · iScience · doi:10.1016/j.isci.2024.109893 · Cited by 44
Surface Engineering on Bacteria for Tumor Immunotherapy: Strategies and Perspectives
Fu, L., He, Q., Lu, X., Hu, L., Qian, H., & Pei, P. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202405304 · Cited by 44
Zeng, X., Jia, H., Zhang, X., Wang, X., Wang, Z., Gao, Z., Yuan, Y., & Yue, T. (2021) · Food & Function · doi:10.1039/d1fo01729b · Cited by 45
Reuniting philosophy and science to advance cancer research
Pradeu, T., Daignan‐Fornier, B., Ewald, A. J., Germain, P., Okasha, S., Plutynski, A., Benzekry, S., Bertolaso, M., Bissell, M. J., Brown, J. S., et al. (2023) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12971 · Cited by 44
Self-citationGut microbiota and its therapeutic implications in tumor microenvironment interactions
Feng, P., Xue, X., Bukhari, I., Qiu, C., Li, Y., Zheng, P., & Mi, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1287077 · Cited by 43
Qin, S., Xie, B., Wang, Q., Yang, R., Sun, J., Hu, C., Liu, S., Tao, Y., & Xiao, D. (2024) · MedComm · doi:10.1002/mco2.551 · Cited by 43
Alum, E. U., Uti, D. E., Ugwu, O. P.-C., Alum, B. N., Edeh, F. O., & Ainebyoona, C. (2025) · Discover Oncology · doi:10.1007/s12672-025-02352-2 · Cited by 43
A rapid screening platform to coculture bacteria within tumor spheroids
Harimoto, T., Deb, D., & Danino, T. (2022) · Nature Protocols · doi:10.1038/s41596-022-00723-5 · Cited by 43
The role of oral microbiota in cancer
Lan, Z., Liu, W.-J., Cui, H., Zou, K., Chen, H. H., Zhao, Y., & Yu, G. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1253025 · Cited by 42
Bridging Discovery and Treatment: Cancer Biomarker
Liu, H., Karsidag, I., Golin, R., & Wu, G. (2025) · Cancers · doi:10.3390/cancers17223720 · Cited by 42
Chen, J., Li, T., Liang, J., Huang, Q., Huang, J., Ke, Y., & Sun, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112443 · Cited by 42
Khannous‐Lleiffe, O., Willis, J. R., Saus, E., Moreno, V. R., Castellví-Bel, S., Gabaldón, T., & On Behalf Of The Criprev Consortium (2022) · Cancers · doi:10.3390/cancers15010120 · Cited by 41
Microbial metabolites are involved in tumorigenesis and development by regulating immune responses
Liu, J., Tian, R., Sun, C., Guo, Y., Dong, L., Li, Y., & Song, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290414 · Cited by 41
Tang, F., Deng, M., Xu, C., Yang, R., Ji, X., Hao, M., Wang, Y., Tian, M., Geng, Y., & Miao, J. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1328419 · Cited by 41
Bacterial extracellular vesicles for gut microbiome–host communication and drug development
Qian, D., Xu, P., Wang, X., Du, C., Zhao, X., & Xu, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.008 · Cited by 41
Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy
Bolte, L. A., Björk, J. R., Gaćeša, R., & Weersma, R. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.025 · Cited by 43
Using all our genomes: Blood‐based liquid biopsies for the early detection of cancer
Adams, E. W., Sepich‐Poore, G. D., Miller‐Montgomery, S., & Knight, R. D. (2022) · View · doi:10.1002/viw.20200118 · Cited by 41
Self-citationCurrent Status and Future Directions of Bacteria-Based Immunotherapy
Tang, Q., Peng, X., Xu, B., Zhou, X., Chen, J., & Cheng, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.911783 · Cited by 41
Yue, K., Sheng, D., Xue, X., Zhao, L., Zhao, G., Jin, C., & Zhang, L. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00904-23 · Cited by 40
The Diagnostic Potential of the Human Blood Microbiome: Are We Dreaming or Awake?
Sciarra, F., Franceschini, E., Campolo, F., & Venneri, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310422 · Cited by 40
Molecular crosstalk between polyphenols and gut microbiota in cancer prevention
Zeb, F., Naqeeb, H., Osaili, T. M. I., Faris, M. E., Ismail, L. C., Obaid, R. S., Naja, F., Radwan, H. M., Hasan, H. A., Hashim, M. S., et al. (2024) · Nutrition Research · doi:10.1016/j.nutres.2024.01.012 · Cited by 40
Malakar, S., Sutaoney, P., Madhyastha, H., Shah, K., Chauhan, N. S., & Banerjee, P. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14505 · Cited by 40
Human intestinal microbiome: Role in health and disease
Cantón, R., Ramos, P. D. L., Botella, A. G., García‐Lledó, A., Hernández‐Sampelayo, T., Gómez‐Pavón, J., del Castillo, J. M. G., Martín-Delgado, M. C., Martín‐Sánchez, F. J., Martínez‐Sellés, M., et al. (2024) · Revista Española de Quimioterapia · doi:10.37201/req/056.2024 · Cited by 40
Surface nanocoating of bacteria as a versatile platform to develop living therapeutics
Cao, Z., & Liu, J. (2024) · Nature Protocols · doi:10.1038/s41596-024-01019-6 · Cited by 40
Tao, M., Xie, Y., Fan, X., Yan, X., Fan, W., Cao, R., Li, M., Li, R., & Wang, L. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144719 · Cited by 40
Liao, K., Wen, J., Liu, Z., Zhang, B., Zhang, X., Fu, Y., Zhang, W., Hu, H., Ai, K., Zhu, W., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102820 · Cited by 40
Hao, W., Cha, R., Wang, M., Zhang, P., & Jiang, X. (2022) · Nanoscale Horizons · doi:10.1039/d1nh00315a · Cited by 40
Comprehensive histological imaging of native microbiota in human glioma
Zhao, J., He, D., Lai, H. M., Xu, Y., Luo, Y., Li, T., Liang, J., Yang, X., Guo, L., Ke, Y., et al. (2022) · Journal of Biophotonics · doi:10.1002/jbio.202100351 · Cited by 40
Current understanding of the human microbiome in glioma
Liang, J., Li, T., Zhao, J., Wang, C., & Sun, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.781741 · Cited by 40
Gut microbial response to host metabolic phenotypes
Hou, J., Xiang, J., Li, D., Liu, X., & Pan, W. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1019430 · Cited by 40
Jiang, M., Yang, Z., Dai, J., Wu, T., Jiao, Z., Yu, Y., Kang, N., Chen, W., & Yang, A. (2023) · MedComm · doi:10.1002/mco2.376 · Cited by 39
RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond
Ding, Y.-P., Liu, C., & Yu, K. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00648-1 · Cited by 39
The Role of Gut Microbiota in Tumor Immunotherapy
Wu, M., Bai, J., Ma, C., Wei, J., & Du, X. (2021) · Journal of Immunology Research · doi:10.1155/2021/5061570 · Cited by 39
Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches
Miserocchi, G., Spadazzi, C., Calpona, S., Rosa, F. D., Usai, A., Vita, A. D., Liverani, C., Cocchi, C., Vanni, S., Calabrese, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060854 · Cited by 39
Wang, N., Yang, J., Han, W., Han, M., Liu, X., Jiang, L., Cao, H., Jing, M., Sun, T., & Xu, J. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1029905 · Cited by 39
Immunotherapies against HER2-Positive Breast Cancer
Duro‐Sánchez, S., Alonso, M. R., & Arribas, J. (2023) · Cancers · doi:10.3390/cancers15041069 · Cited by 40
Effenberger, M., Waschina, S., Bronowski, C., Sturm, G., Tassiello, O., Sommer, F., Zollner, A., Watschinger, C., Grabherr, F., Gstir, R., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000182 · Cited by 40
The role of the symbiotic microecosystem in cancer: gut microbiota, metabolome, and host immunome
Xue, X., Li, R., Chen, Z., Li, G., Liu, B., Guo, S., Yue, Q., Yang, S., Xie, L., Zhang, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1235827 · Cited by 39
Chen, Q., Zhu, Y., Wang, K., Wang, X., Zhang, Y., Zhou, M., Du, J., Qu, X., Shi, Z., Zhang, Y., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101994 · Cited by 38
Mou, W., Deng, Z., Zhu, L., Jiang, A., Lin, A., Xu, L., Deng, G., Huang, H., Guo, Z., Zhu, B., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu1727 · Cited by 38
Cavallucci, V., Palucci, I., Fidaleo, M., Mercuri, A., Masi, L., Emoli, V., Bianchetti, G., Fiori, M. E., Bachrach, G., Scaldaferri, F., et al. (2022) · Biomolecules · doi:10.3390/biom12091256 · Cited by 38
Computational methods and challenges in analyzing intratumoral microbiome data
Wang, Q., Liu, Z., Ma, A., Li, Z., Liu, B., & Ma, Q. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.01.011 · Cited by 37
“Given that current cancer treatments cannot address refractory metastatic cancers, drug-resistant cancers, and cancers that evade immune clearance, ‘ bugs as drugs ’ (such as microbial therapies) may provide solutions to these unresolvable clinical needs [2,63].”
BackgroundInfluentialInfluence of Microbiota on Tumor Immunotherapy
Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 37
Li, W., Shangguan, W., Huang, W., Zhao, J., Zhu, Y., Xie, M., Yu, Y., Yang, Q., Zheng, J., Yang, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202504688 · Cited by 37
Recent advances in cancer immunotherapy
Sun, Q., Melino, G., Amelio, I., Jiang, J., Wang, Y., & Shi, Y. (2021) · Discover Oncology · doi:10.1007/s12672-021-00422-9 · Cited by 37
Current status and future perspective of immune checkpoint inhibitors in colorectal cancer
Zhou, C., Cheng, X., & Tu, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.023 · Cited by 37
Chen, Y., Fei, F., Ding, L.-L., Wen, S., Ren, C., & Gong, A. (2024) · Food & Function · doi:10.1039/d3fo04806c · Cited by 36
Microbiome and Prostate Cancer: Emerging Diagnostic and Therapeutic Opportunities
Kim, S. J., Park, M., Choi, A., & Yoo, S. (2024) · Pharmaceuticals · doi:10.3390/ph17010112 · Cited by 36
Oral microbial signatures associated with age and frailty in Canadian adults
DeClercq, V., Wright, R., Nearing, J. T., & Langille, M. G. I. (2024) · Scientific Reports · doi:10.1038/s41598-024-60409-8 · Cited by 37
From nature to clinic: Quercetin’s role in breast cancer immunomodulation
Fang, L., Gao, D., Wang, T., Zhao, H., Zhang, Y., & Wang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1483459 · Cited by 36
Jannati, S., Patel, A., Patnaik, R., & Banerjee, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125521 · Cited by 36
Recent research progress and clinical status of immunotherapy for colorectal cancer
Huo, Z., Liu, G., & Li, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.089 · Cited by 36
Integrative systems biology approaches for analyzing microbiome dysbiosis and species interactions
Rehman, S. S. U., Nasar, M. I., Mesquita, C. S., Khodor, S. A., Notebaart, R. A., Ott, S., Mundra, S., Arasardanam, R. P., Muhammad, K., & Alam, M. T. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf323 · Cited by 37
Yu, H., Du, Y., He, Y., Sun, Y., Li, J., Jia, B., Chen, J., Peng, X., An, T., Li, J., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.06.013 · Cited by 36
Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance
Chai, Q., Li, D., Zhang, M., Gu, Y., Li, A., Wu, X., Liu, X., & Liu, J. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101277 · Cited by 36
Wang, Z., Guo, K., Liu, Y., Huang, C., & Wu, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.10.004 · Cited by 36
The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
Modica, M. D., Arlotta, V., Sfondrini, L., Tagliabue, E., & Triulzi, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.947188 · Cited by 36
Dietrich, A., Matchado, M. S., Zwiebel, M., Ölke, B., Lauber, M., Lagkouvardos, I., Baumbach, J., Haller, D., Brandl, B., Skurk, T., et al. (2022) · Microbial Genomics · doi:10.1099/mgen.0.000852 · Cited by 36
Regulation of T cell repertoires by commensal microbiota
Kim, K. S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1004339 · Cited by 37
Gut-spine axis: a possible correlation between gut microbiota and spinal degenerative diseases
Morimoto, T., Kobayashi, T., Kakiuchi, T., Esaki, M., Tsukamoto, M., Yoshihara, T., Hirata, H., Yabuki, S., & Mawatari, M. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1290858 · Cited by 36
Yeo, K. K. L., Connell, J. T., Bouras, G. S., Smith, E., Murphy, W., Hodge, J.-C., Krishnan, S., Wormald, P., Valentine, R. J., Psaltis, A. J., et al. (2024) · Archives of Microbiology · doi:10.1007/s00203-024-03985-7 · Cited by 35
Zhou, Z., Zhang, R., Zhang, Y., Xu, Y., Wang, R., Chen, S., Lv, Y., Chen, Y., Ren, Y., Luo, P., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217273 · Cited by 35
Engineered bacteria: Strategies and applications in cancer immunotherapy
Zhang, S., Li, R., Xu, Y., Liu, R., Sun, D., & Dai, Z. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.11.001 · Cited by 35
Designing live bacterial therapeutics for cancer
Lee, J., McClure, S., Weichselbaum, R. R., & Mimee, M. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115579 · Cited by 35
Mejía-Caballero, A., Salas-Villagrán, V. A., Jiménez-Serna, A., & Farrés, A. (2021) · Journal of Industrial Microbiology & Biotechnology · doi:10.1093/jimb/kuab052 · Cited by 35
Circulating microbiome DNA: An emerging paradigm for cancer liquid biopsy
Chen, H., Ma, Y., Liu, Z., Li, J., Li, X., Yang, F., & Qiu, M. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.036 · Cited by 35
You, L., Zhou, J., Xin, Z., Hauck, J. S., Na, F., Tang, J., Zhou, X., Lei, Z., & Ying, B. (2022) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbac005 · Cited by 35
Vaginal microbiota and HPV clearance: A longitudinal study
Shi, W., Zhu, H., Yuan, L., Chen, X., Huang, X., Wang, K., & Li, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955150 · Cited by 35
Siddiqui, N. A., Ventrola, A. J., Hartman, A. R., Konare, T., Kamble, N. S., Thomas, S. C., Madaan, T., Kharofa, J. R., Sertorio, M. G., & Kotagiri, N. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202870 · Cited by 35
Fusobacterium nucleatum : a novel immune modulator in breast cancer?
Little, A., Tangney, M., Tunney, M. M., & Buckley, N. E. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.9 · Cited by 35
The intratumoral microbiota: From microniches to single cells
Bullman, S. (2023) · Cell · doi:10.1016/j.cell.2023.03.012 · Cited by 35
Cell membrane-coated nanoparticles for targeting carcinogenic bacteria
Sun, L., Wang, D., Feng, K., Zhang, J. A., Gao, W., & Zhang, L. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115320 · Cited by 34
Benej, M., Hoyd, R., Kreamer, M., Wheeler, C. E., Grencewicz, D. J., Choueiry, F., Chan, C. H. F., Zakharia, Y., Ma, Q., Dodd, R. D., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0367 · Cited by 34
Hu, J., Ran, S., Huang, Z., Liu, Y., Hu, H., Zhou, Y., Ding, X., Yin, J., & Zhang, Y. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.06.042 · Cited by 34
Thapa, R., Magar, A. T., Shrestha, J., Panth, N., Idrees, S., Sadaf, T., Bashyal, S., Elwakil, B. H., Sugandhi, V. V., Rojekar, S. V., et al. (2024) · MedComm · doi:10.1002/mco2.70018 · Cited by 34
The bacterial microbiome and cancer: development, diagnosis, treatment, and future directions
Qasem, H., & El-Sayed, W. M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01523-9 · Cited by 34
Race is a key determinant of the human intratumor microbiome
Luo, M., Liu, Y., Hermida, L. C., Gertz, E. M., Zhang, Z., Li, Q., Diao, L., Ruppin, E., & Han, L. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.007 · Cited by 34
The tumor mycobiome: A paradigm shift in cancer pathogenesis
Li, X., & Saxena, D. (2022) · Cell · doi:10.1016/j.cell.2022.09.013 · Cited by 34
Exploring the Involvement of Gut Microbiota in Cancer Therapy-Induced Cardiotoxicity
Kunika, Frey, N., & Rangrez, A. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087261 · Cited by 34
Esophageal microflora in esophageal diseases
Zou, Q., Feng, L., Cai, X., Qian, Y., & Xu, L. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1145791 · Cited by 34
He, J., Li, H., Jia, J., Liu, Y., Zhang, N., Wang, R., Qu, W., Liu, Y., & Jia, L. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00157-9 · Cited by 34
Association between gut microbiota and glioblastoma: a Mendelian randomization study
Wang, S., Yin, F., Guo, Z., Li, R., Sun, W., Wang, Y., Geng, Y., Sun, C., & Sun, D. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2023.1308263 · Cited by 34
Sepich‐Poore, G. D., Guccione, C., Laplane, L., Pradeu, T., Curtius, K., & Knight, R. (2022) · BioEssays · doi:10.1002/bies.202100252 · Cited by 33
Self-citation
Metadata
- Authors
- Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R.
- Affiliations
- Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA.
- Université Paris-Sud (FR)
- Weizmann Institute of Science (IL)
- University of California San Diego (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Knight, Rob
- ORCID
- Venue
- Science
- Published
- 2021-03-26
- Volume
- 371
- Issue
- 6536
- Pages
- 91-97
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8767999
- OpenAlex
- W3138215020
- Cited by
- 1,332
- References
- 176
- Citations by year
- 2026: 231 · 2025: 310 · 2024: 294 · 2023: 274 · 2022: 161 · 2021: 62
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-09-26)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (F30 CA243480, R01CA255206)
- RHU Torino Lumière (ANR-16-RHUS-0008)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- microbiome, cancer, gut microbiota, antitumor immunity, microbial metabolites, Toll-like receptors, immune checkpoint inhibitors, intratumoral bacteria, bacteriophages, gastrointestinal cancer, cancer immunotherapy, microbiota modulation, engineered bacteria, Rous sarcoma virus, viral oncogenesis, molecular mimicry
- MeSH terms
- Gastrointestinal Microbiome, Host Microbial Interactions, Anti-Bacterial Agents, Antineoplastic Agents, Bacteria, Genetic Engineering, Humans, Immunotherapy, Lymphoid Tissue, Neoplasms, Virus Physiological Phenomena, Bacterial Physiological Phenomena, Oncolytic Virotherapy, Adaptive Immunity, Immunomodulation, Tumor Microenvironment, Carcinogenesis, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.